Oct 24, 2020
Cancerous tumors have their own microbiome, a unique method of
energy production, strategies for evading host immune systems,
specialized extracellular vesicles, and one real goal: to expand
and replicate at the expense of the environment.
Press play to discover:
Returning guest, Jo Bhakdi, is the founder of Quantgene, the
world’s leader in liquid biopsy technologies when it comes to
precision. It’s a technology that uses next-generation genome
sequencing in combination with AI and cloud systems to detect
cancer in the early stages in the blood.
The team at Quantgene has pioneered the ability to have
single-molecule precision across a very high number of locations on
DNA. This core sequencing technology is being embedded in advanced
AI cloud systems that also have whole exome sequencing data.
Together with genetics, medical records, and family history data,
these technologies render a 360-degree precision profile for each
patient. In essence, it’s a giant, sensitive detection tool for
cancer, and it holds promise for fulfilling the same role for
other diseases.
Bhakdi discusses all aspects of cancer, including how it spreads, how it’s acted upon epigenetically, and the potential of certain therapies. In particular, he says, “One of the greatest breakthroughs in my opinion, that is not fully exploited yet, is immunotherapy, because every time you have something very complex…you need another system that’s equally complex and capable to indirectly handle it.”
He talks about the indirect screening trade-offs of liquid biopsies, the general problem of over-diagnosing, the relationship between the heterogeneity of tumors and mutation profiles, and more.
Learn more at https://www.quantgene.com/.
Available on Apple Podcasts: apple.co/2Os0myK